Drug Index



Mechanism :

Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.

Indication :

• Transfusional Hemosiderosis

• Non-transfusion-dependent thalassemia

Contraindications :

Hypersensitivity, Renal OR liver failure, Thrombocytopenia.

Dosing :


Transfusional iron overload:

2 years of age or older: Initial dose: 20 mg/kg once a day. Maintenance dose: 20 to 40 mg/kg/day. Maximum dose: 40 mg/kg/day.


10 mg/kg orally once daily.

Adverse Effect :

Renal toxicity, proteinuria, hepatic toxicity, GI hemorrhage, bone marrow suppression, hypersensitivity, auditory and ocular abnormalities.

Interaction :

Aluminium: Possible physicochemical interaction.
Anticoagulants: Increase the risk for gastrointestinal ulceration/irritation and/or GI bleeding. If these two agents must be used, patients need to be closely monitored for signs and symptoms of GI toxicity.
Etravirine, Tofacitinib (and other CYP3A4 substrates): When administered concomitantly with deferasirox, may experience a decrease in serum concentration. It is recommended to monitor therapy.

03/07/2020 02:17:59 Deferasirox
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0